Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Annals of the Rheumatic Diseases|April 23, 2017
Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosusChi Chiu Mok, Ling Yin Ho, Sau Mei Tse, et al.
Arthritis Care & Research|August 27, 2014
Validation of the LupusPRO in Chinese patients from Hong Kong with systemic lupus erythematosusChi Chiu Mok, Mark Kosinski, Ling Yin Ho, et al.
Lupus|January 18, 2023
Relationship between the EULAR/ACR classification criteria and organ damage in systemic lupus erythematosusChi Chiu Mok, Yuen Kwan Chung, Carolyn Lee, et al.
Therapeutic Advances in Musculoskeletal Disease|June 2, 2022
Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in ANA-positive Chinese patientsYuen Kwan Chung, Ling Yin Ho, Carolyn Lee, et al.
Medicine|June 25, 2013
Prevalence of the antiphospholipid syndrome and its effect on survival in 679 Chinese patients with systemic lupus erythematosus: a cohort studyChi Chiu Mok, Pak To Chan, Ling Yin Ho, et al.
Inflammation|May 6, 2023
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Associated with Disease Activity and Risk of Incident Cardiovascular Disease in Patients with Systemic Lupus ErythematosusChi Chiu Mok, Ling Yin Ho, Kar Li Chan, et al.
Clinical Rheumatology|July 18, 2018
Serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus: a longitudinal cohort analysisChi Chiu Mok, Eric T Bro, Ling Yin Ho, et al.
Arthritis Care & Research|September 6, 2012
High-sensitivity C-reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosusChi Chiu Mok, Daniel J Birmingham, Ling Yin Ho, et al.
Frontiers in Medicine|October 5, 2020
Trend of Survival of a Cohort of Chinese Patients With Systemic Lupus Erythematosus Over 25 YearsChi Chiu Mok, Ling Yin Ho, Kar Li Chan, et al.
Clinical Rheumatology|November 17, 2022
Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapiesChi Chiu Mok, Ling Yin Ho, Sau Mei Tse, et al.
Pageof 3